Heterocyclic hydrazones as novel anti-cancer agents

C - Chemistry – Metallurgy – 07 – D

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07D 403/12 (2006.01) A61K 31/44 (2006.01) A61P 35/00 (2006.01) C07D 401/12 (2006.01) C07D 413/12 (2006.01) C07D 417/12 (2006.01)

Patent

CA 2413971

The invention relates to novel 2-benzimidazolyl-, 2-benzoxazolyl- and 2- benzothiazolyl hydrazones that are derived from 2-formylpyridine, 2- acylpyridines, acetyldiazines and acetyl(iso)quinolines. The invention also relates to a novel method for producing 2-benzimidazolyl-, 2-benzoxazolyl- and 2-benzothiazolyl hydrazones and to their use as useful anti-cancer therapeutic agents. The novel compounds are also active against multidrug-resistant cancer cells.

L'invention concerne des hydrazones 2-benzimidazolyle, 2-benzoxazolyle et 2-benzothiazolyle, qui dérivent de 2-formylpyridine, 2-acylpyridines, d'acétyldiazines et d'acétyle(iso)quinoléines. Elle concerne également un procédé de production d'hydrazones 2-benzimidazolyle, 2-benzoxazolyle et 2-benzothiazolyle et leur utilisation dans la thérapie de lutte contre le cancer. Ces composés sont en outre actifs contre les cellules cancéreuses résistantes à l'action de plusieurs médicaments.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Heterocyclic hydrazones as novel anti-cancer agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heterocyclic hydrazones as novel anti-cancer agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic hydrazones as novel anti-cancer agents will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1456340

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.